Tempest Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.79.

EBIT: As of FY2025 Q3, the actual value is USD -3.683 M, beating the estimate of USD -6.8 M.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $3.5 million, compared to $10.6 million for the same period in 2024, representing a decrease of 67%.
• Research and Development Expenses: Decreased by $7.0 million to $0.6 million for the three months ended September 30, 2025, compared to the same period in 2024, primarily due to re-prioritizing efforts towards exploring strategic alternatives initiated in April 2025.
• General and Administrative Expenses: Remained relatively stable at $3.0 million for the three months ended September 30, 2025, compared to the same period in 2024.

Cash Flow

• Cash Used in Operating Activities: For the nine months ended September 30, 2025, cash used in operating activities was $23.2 million, compared to $22.9 million for the same period in 2024.
• Cash Provided by Financing Activities: For the nine months ended September 30, 2025, cash provided by financing activities was $0.5 million, compared to $6.5 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Tempest Therapeutics, Inc. plans to explore a full range of strategic alternatives to advance its clinical-stage programs and maximize stockholder value. This includes potential mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions.
• Non-Core Business: The company has reduced its workforce significantly and transitioned key executives to consulting roles to extend its capital resources while exploring strategic alternatives.
• Priority: The company is focused on advancing its lead product candidates, Amezalpat and TPST-1495, into further clinical trials, subject to securing additional financial resources.